@booklet {1604226,
	title = {Building the Supply Chain for COVID-19 Vaccines},
	journal = {Harvard Business Publishing},
	year = {2021},
	abstract = {
	In November 2020 as the world grappled with a over 50 million cases of Coronavirus disease 2019 (COVID-19) and over 1 million deaths, all eyes were focused on the development and manufacturing of COVID-19 vaccines. This case traces the complex set of activities involved in the development, regulatory approval, production, and distribution of COVID-19 vaccines. It describes the resources, information, cooperation, and decision making that went into this unprecedented effort.\&nbsp;\&nbsp;It poses some of the difficult strategic and operational decision dilemmas faced by country governments, purchasers, vaccine developers, and manufacturers in designing the overall supply chain for COVID-19 vaccines.



	[[{"fid":"3924271","view_mode":"default","type":"media","attributes":{"style":"border-width: 1px; border-style: solid; width: 800px; height: 914px;","alt":"Vaccine Development Timeline","class":"media-element file-default"}}]]



	Learning Objectives:\&nbsp;A productive class discussion will allow students to appreciate the development, regulatory approval, production, and distribution processes for a pandemic vaccine;\&nbsp;The complexity and inter-relationships between different activities and actors in the vaccine supply chain;\&nbsp;The role of manufacturing flexibility in managing uncertain demand and supply;\&nbsp;and the importance of a portfolio approach in sourcing/purchasing technology which is under development.



	Keywords:\&nbsp;product development, supply chain management, manufacturing, public-private partnerships, health care delivery, public health, vaccine development, clinical trials, pandemic response, COVID-19



	
	



	\&nbsp;



	\&nbsp;

},
	author = {Marshall Fisher and Kateryna Kharenko and Canberk Ucel and Yadav, Prashant}
}
